Anhui New Peak North Carolina was established in July
Release time:
2020-08-21
Anhui Zhongwang and Jianfeng North Card Merger and Reorganization
Anhui New Jianfeng North Card was established in March
News from our newspaper After several months of integration and adjustment, Anhui Zhongwang Pharmaceutical Co., Ltd. and Anhui Jianfeng North Card Pharmaceutical Co., Ltd., two subsidiaries of Shanghai Beika Pharmaceutical Technology Co., Ltd., completed the reorganization and merger in September 7, established "Anhui New Peak North Card Pharmaceutical Co., Ltd".
The newly established New Jianfeng Beika Pharmaceutical Co., Ltd. is located in Anhui Dongzhe Economic Development Zone, covering an area of 280mu, with a registered capital of RMB 1.2 .5 billion yuan and a total investment of RMB 3 .7 billion yuan. It is a high-tech and innovative enterprise integrating R & D, production and sales, the main products include small molecule targeted generic drugs, cytotoxic and highly active products, quinolone anti-infective drug platforms, specialty varieties and advanced intermediates, etc. At the same time, the contract custom production CDMO mode has also entered the substantive operation stage. The company implements strict GMP standard management and product quality control, and has passed ISO9001 , 14001 , OHSAS18000 certification, and established Chizhou Enterprise Technology Research and Development Center. And in 2019 years 11 January to obtain a pharmaceutical production license.
In terms of product research and technology research, New Jianfeng North Carolina Pharmaceutical relies on the research and development team and academician expert workstations of Shanghai North Carolina, and has also established long-term industry-university-research cooperation with scientific research institutions such as Chinese Academy of Sciences, China Pharmaceutical University, Fudan University, Shanghai Engineering Research Center for Molecular Therapy and New Drug Creation, and is equipped with complete synthesis laboratories and analysis laboratories, the main research and development equipment can meet the research and development and production of grams to 100 kilograms. In terms of safety and environmental protection management, a large amount of money has been invested in the sewage treatment station in the plant area, and full-time safety management personnel have been equipped to establish a three-level safety management system.After the integration of Anhui New Jianfeng North Card Pharmaceutical Co., Ltd. will continue to undertake the second batch of major emerging industrial projects of "Triple and One Innovation" in Anhui Province. On the basis of the original 2
workshops and1 GMP pilot workshops, the second phase project of adding 3 GMP workshops and 3 advanced pharmaceutical intermediate workshops is also under construction, actively cooperating with domestic pharmaceutical preparation enterprises to jointly build a green pharmaceutical platform, enabling more CDMO/CMO development. (Zhang Yang Lina)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page